SI
BIO icon

Sapience Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Sapience Investments’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-28,365
Closed -$6.3M – 76
2017
Q3 		$6.3M Buy
28,365
+1,120
+4% +$252K 0.88% 53
2017
Q2 		$6.17M Sell
27,245
-6,239
-19% -$1.36M 0.97% 55
2017
Q1 		$6.67M Buy
33,484
+10,415
+45% +$2.01M 1.09% 52
2016
Q4 		$4.21M Buy
+23,069
New +$3.93M 1.29% 44

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
HCM
Hitchwood Capital Management New York $184M AUM 3.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Sapience Investments's BIO Position: Q4 2017 in Review

Sapience Investments sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2017, closing a stake of 28,365 shares — an estimated $6.3M sold.

Sapience Investments first reported a position in BIO in Q4 2016 and held it in 4 quarters. The position peaked at $6.67M in Q1 2017. 302 funds tracked by Wall St. Rank hold BIO as of Q4 2017.

  • Sapience Investments reported no remaining Bio-Rad Laboratories Class A position as of Q4 2017 after selling out during the quarter.
  • Sapience Investments sold 28,365 Bio-Rad Laboratories Class A shares in Q4 2017, an estimated $6.3M.
  • Sapience Investments first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and held it in 4 quarters.
  • Sapience Investments's Bio-Rad Laboratories Class A position peaked at $6.67M in Q1 2017.
  • 302 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2017.

Based on Sapience Investments's 13F filing for Q4 2017, filed 14 Feb 2018.